Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Wave Life Sciences (WVE) Non-Current Deffered Revenue (2016 - 2025)

Wave Life Sciences' Non-Current Deffered Revenue history spans 10 years, with the latest figure at $7.8 million for Q4 2025.

  • For Q4 2025, Non-Current Deffered Revenue rose 27.86% year-over-year to $7.8 million; the TTM value through Dec 2025 reached $7.8 million, up 27.86%, while the annual FY2025 figure was $7.8 million, 27.86% up from the prior year.
  • Non-Current Deffered Revenue reached $7.8 million in Q4 2025 per WVE's latest filing, down from $11.7 million in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $130.8 million in Q1 2023 to a low of $4.2 million in Q2 2025.
  • Average Non-Current Deffered Revenue over 5 years is $57.2 million, with a median of $75.9 million recorded in 2022.
  • Peak YoY movement for Non-Current Deffered Revenue: surged 91.17% in 2021, then crashed 90.83% in 2024.
  • A 5-year view of Non-Current Deffered Revenue shows it stood at $77.5 million in 2021, then increased by 2.96% to $79.8 million in 2022, then plummeted by 80.44% to $15.6 million in 2023, then crashed by 60.91% to $6.1 million in 2024, then rose by 27.86% to $7.8 million in 2025.
  • Per Business Quant, the three most recent readings for WVE's Non-Current Deffered Revenue are $7.8 million (Q4 2025), $11.7 million (Q3 2025), and $4.2 million (Q2 2025).